Supriya Lifescience IPO Listing: Shares make stellar debut on exchanges; lists at 55% premium to Rs 425

The shares of Supriya Lifescience made a stellar debut on the stock market. Supriya Lifescience shares were listed at a premium of 55.11 % to Rs 425 per share against its issue price of Rs 274 on the BSE on Tuesday. Investors made a profit of Rs 151 apiece on the listing of shares of active pharmaceutical ingredients supplier. On the NSE, the shares of Supriya Lifescience opened at Rs 421, a gain of Rs 147 or 53.65%

The market capitalisation of Supriya Lifescience on the BSE stood at Rs 3,420.52 crore during the listing.  

In the pre-open, around 9.35 am, shares of Supriya Lifescience were trading with over 50% premium to Rs 419 per share on the BSE.  

See Zee Business Live TV Streaming Below:

Supriya Lifescience IPO was subscribed 71.51 times on December 20, the final day of the bidding.  The issue had received bids for 103.89 crore equity shares against the offer size of 1.45 crore shares on the final day.

Earlier, Zee Business Managing Editor Anil Singhvi has predicted a strong listing for this public offer. "Expected to list in Rs 400-450 range against issue price of Rs 274," Singhvi had said.  

Aayush Agrawal, Senior Analyst, Swastika Investmart Ltd, too had said the grey market is indicating a listing gain of more than 50%. "Supriya Lifesciences, another good company from the API segment, garnered lots of investors' interest on the back of strong financials and attractive valuations. We are expecting a strong listing from this company as market sentiments have improved and the IPO witnessed strong subscription numbers," Aayush said on Monday.  

The manufacturers and suppliers of active pharmaceutical ingredients (APIs), Supriya Lifescience, plans to use the proceeds from the fresh issue for funding capital expenditure requirements, repaying debt and general corporate purposes. About 75 per cent of the issue was reserved for qualified institutional buyers (QIBs), 15 per cent for non-institutional investors and the remaining 10 per cent for retail investors.  Investors can bid for a minimum of 54 equity shares and in multiples thereof.    

Incorporated in March 2008, the company had product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anesthetic, vitamin, anti-asthmatic and anti-allergic, as per PTI

From April 1, 2020, until October 31, 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors.